Diego Cadavid to Interferon-beta
This is a "connection" page, showing publications Diego Cadavid has written about Interferon-beta.
Connection Strength
0.410
-
Cadavid D, Jurgensen S, Lee S. Impact of natalizumab on ambulatory improvement in secondary progressive and disabled relapsing-remitting multiple sclerosis. PLoS One. 2013; 8(1):e53297.
Score: 0.097
-
Cheriyan J, Kim S, Wolansky LJ, Cook SD, Cadavid D. Impact of inflammation on brain volume in multiple sclerosis. Arch Neurol. 2012 Jan; 69(1):82-8.
Score: 0.090
-
Cadavid D, Kim S, Peng B, Skurnick J, Younes M, Hill J, Wolansky LJ, Cook SD. Clinical consequences of MRI activity in treated multiple sclerosis. Mult Scler. 2011 Sep; 17(9):1113-21.
Score: 0.087
-
Pachner AR, Cadavid D, Wolansky L, Skurnick J. Effect of anti-IFN{beta} antibodies on MRI lesions of MS patients in the BECOME study. Neurology. 2009 Nov 03; 73(18):1485-92.
Score: 0.078
-
Wolansky LJ, Haghighi MH, Sevdalis E, Cook SD, Sethi N, Liu J, Joseph G, Tulloch K, Cadavid D. Safety of serial monthly administration of triple-dose gadopentetate dimeglumine in multiple sclerosis patients: preliminary results of the BECOME trial. J Neuroimaging. 2005 Jul; 15(3):289-90.
Score: 0.058